The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate if vasopressin can elevate systemic arterial blood
pressures without having a significant effect on pulmonary arterial pressures. Because
patients who have undergone Fontan procedures rely on low pressures across the pulmonary
vascular bed to maintain cardiac output, vasoactive agents that concomitantly increase
systemic and pulmonary pressures may have a deleterious effect in this specific patient
population.
Hypothesis: In patients with Fontan physiology, vasopressin will increase systemic BP by 20%
above baseline, without increasing the transpulmonary gradient.